West Pharmaceutical Services, Inc. (BVMF:W2ST34)

Revenue

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014
Proprietary Products Revenue	2.44B	2.33B	2.40B
Proprietary Products Revenue Growth	4.70%	-2.62%	-0.40%
Contract-Manufactured Products Revenue	573.70M	558.70M	552.50M
Contract-Manufactured Products Revenue Growth	2.69%	1.12%	15.01%
Revenue (Total)	3.02B	2.89B	2.95B
Revenue (Total) Growth	4.31%	-1.92%	2.18%

EBIT

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014
Proprietary Products Operating Profit	629.80M	577.80M	710.10M
Proprietary Products Operating Profit Growth	9.00%	-18.63%	-9.47%
Contract-Manufactured Products Operating Profit	69.80M	72.30M	72.10M
Contract-Manufactured Products Operating Profit Growth	-3.46%	0.28%	19.37%
Operating Income (Other)	-111.70M	-80.20M	-106.20M
Operating Income (Total)	587.90M	569.90M	676.00M
Operating Income (Total) Growth	3.16%	-15.70%	-7.90%

Key Performance Indicators

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014
Organic Net Sales Growth	-1.50%	1.60%

Updated Sep 30, 2025. Data Source: Fiscal.ai.